All Stories

  1. Mucus-penetrating and permeation enhancer albumin-based nanoparticles for oral delivery of macromolecules: application to bevacizumab
  2. Optimization of Enterotoxigenic Escherichia coli (ETEC) Outer Membrane Vesicles Production and Isolation Method for Vaccination Purposes
  3. Encapsulation of Lactobacillus plantarum in casein-chitosan microparticles facilitates the arrival to the colon and develops an immunomodulatory effect
  4. Oral administration of zein-based nanoparticles reduces glycemia and improves glucose tolerance in rats
  5. Evaluación de toxicidad de nanogeles termosensibles en modelo in vivo
  6. Effect of topical berberine in murine cutaneous leishmaniasis lesions
  7. Immune Response after Skin Delivery of a Recombinant Heat-Labile Enterotoxin B Subunit of Enterotoxigenic Escherichia coli in Mice
  8. Oral Immunogenicity of Enterotoxigenic Escherichia coli Outer Membrane Vesicles Encapsulated into Zein Nanoparticles Coated with a Gantrez® AN–Mannosamine Polymer Conjugate
  9. Zein-Based Nanoparticles as Oral Carriers for Insulin Delivery
  10. Development of a Bacterial Nanoparticle Vaccine Against Escherichia coli
  11. Nanoparticles from Gantrez-based conjugates for the oral delivery of camptothecin
  12. Oral Efficacy of a Diselenide Compound Loaded in Nanostructured Lipid Carriers in a Murine Model of Visceral Leishmaniasis
  13. Development of nanostructured systems using natural polymers to optimize the treatment of inflammatory bowel diseases: A prospective study
  14. In vivo testing of mucus-permeating nanoparticles for oral insulin delivery using Caenorhabditis elegans as a model under hyperglycemic conditions
  15. Protection Conferred by Drinking Water Administration of a Nanoparticle-Based Vaccine against Salmonella Enteritidis in Hens
  16. Zein-based nanocarriers for the oral delivery of insulin. In vivo evaluation in Caenorhabditis elegans
  17. Dinámica de la densidad de probabilidad en la región interna de un potencial doble delta de Dirac
  18. Berberine-Loaded Liposomes for the Treatment of Leishmania infantum-Infected BALB/c Mice
  19. Protective Passive Immunity in Escherichia coli ETEC-Challenged Neonatal Mice Conferred by Orally Immunized Dams with Nanoparticles Containing Homologous Outer Membrane Vesicles
  20. Zein-based nanoparticles for the oral delivery of insulin
  21. Zein nanoparticles improve the oral bioavailability of resveratrol in humans
  22. Protein-based nanoparticles for drug delivery purposes
  23. Intranasal delivery system of bacterial antigen using thermosensitive hydrogels based on a Pluronic-Gantrez conjugate
  24. Preparación, radiomarcaje con 99mTc y 67Ga y estudios de biodistribución de nanopartículas de albúmina con recubrimientos poliméricos
  25. In vivo efficacy of bevacizumab-loaded albumin nanoparticles in the treatment of colorectal cancer
  26. Encapsulation of probiotics in soybean protein-based microparticles preserves viable cell concentration in foods all along the production and storage processes
  27. Oral Immunogenicity in Mice and Sows of Enterotoxigenic Escherichia Coli Outer-Membrane Vesicles Incorporated into Zein-Based Nanoparticles
  28. Modulation of the fate of zein nanoparticles by their coating with a Gantrez® AN-thiamine polymer conjugate
  29. Evaluation of Skin Permeation and Retention of Topical Dapsone in Murine Cutaneous Leishmaniasis Lesions
  30. Dissolving Microneedles for Intradermal Vaccination against Shigellosis
  31. Casein nanoparticles in combination with 2-hydroxypropyl-β-cyclodextrin improves the oral bioavailability of quercetin
  32. Nanoparticles from Gantrez® AN-poly(ethylene glycol) conjugates as carriers for oral delivery of docetaxel
  33. In vivo effect of bevacizumab-loaded albumin nanoparticles in the treatment of corneal neovascularization
  34. Mannosylated Nanoparticles for Oral Immunotherapy in a Murine Model of Peanut Allergy
  35. In vitro characterization of new stabilizing albumin nanoparticles as a potential topical drug delivery system in the treatment of corneal neovascularization (CNV)
  36. The effect of thiamine-coating nanoparticles on their biodistribution and fate following oral administration
  37. Understanding the basis of transcutaneous vaccine delivery
  38. Towards a subunit vaccine from a Shigella flexneri ΔtolR mutant
  39. Combination of paromomycin plus human anti-TNF-α antibodies to control the local inflammatory response in BALB/ mice with cutaneous leishmaniasis lesions
  40. Increased Oral Bioavailability of Resveratrol by Its Encapsulation in Casein Nanoparticles
  41. Cyclodextrin-grafted poly(anhydride) nanoparticles for oral glibenclamide administration. In vivo evaluation using C. elegans
  42. Pegylated poly(anhydride) nanoparticles for oral delivery of docetaxel
  43. Pegylated nanoparticles for the oral delivery of nimodipine: Pharmacokinetics and effect on the anxiety and cognition in mice
  44. Evaluation of nanoparticles as oral vehicles for immunotherapy against experimental peanut allergy
  45. Human serum albumin nanoparticles for ocular delivery of bevacizumab
  46. Coencapsulation of cyclodextrins into poly(anhydride) nanoparticles to improve the oral administration of glibenclamide. A screening on C. elegans
  47. Evaluation of the treatment with resveratrol-loaded nanoparticles in intestinal injury model caused by ischemia and reperfusion
  48. Poly(anhydride) nanoparticles containing cashew nut proteins can induce a strong Th1 and Treg immune response after oral administration
  49. Soybean protein-based microparticles for oral delivery of probiotics with improved stability during storage and gut resistance
  50. Maternal Vaccination. Immunization of Sows during Pregnancy against ETEC Infections
  51. Special Issue: Pharmaceutics and Drug Delivery in Spain
  52. A combination of nanosystems for the delivery of cancer chemoimmunotherapeutic combinations: 1-Methyltryptophan nanocrystals and paclitaxel nanoparticles
  53. Optimization and evaluation of zein nanoparticles to improve the oral delivery of glibenclamide. In vivo study using C. elegans
  54. Oral immunotherapy using polymeric nanoparticles loaded with peanut proteins in a murine model of fatal anaphylaxis
  55. Corrigendum to ‘Evaluation of the cytotoxicity, genotoxicity and mucus permeation capacity of several surface modified poly(anhydride) nanoparticles designed for oral drug delivery’ [International Journal of Pharmaceutics 517 (2017) 67-79]
  56. Skin vaccination using microneedles coated with a plasmid DNA cocktail encoding nucleosomal histones of Leishmania spp.
  57. Genotoxic evaluation of poly(anhydride) nanoparticles in the gastrointestinal tract of mice
  58. Supramolecular structure of glibenclamide and β-cyclodextrins complexes
  59. Adjuvants for allergy immunotherapeutics
  60. Effective protection of mice against Shigella flexneri with a new self-adjuvant multicomponent vaccine
  61. Toxicity and biodistribution of orally administered casein nanoparticles
  62. Zein nanoparticles as vehicles for oral delivery purposes
  63. In vitro evaluation of the genotoxicity of poly(anhydride) nanoparticles designed for oral drug delivery
  64. Nanoaggregation of inclusion complexes of glibenclamide with cyclodextrins
  65. Topical immunization using a nanoemulsion containing bacterial membrane antigens
  66. Improved effect of amikacin-loaded Poly (D, L-lactide-co-glycolide) (PLGA) nanoparticles against Planktonic and biofilm cells of Pseudomonas aeruginosa
  67. Effect of the oral administration of nanoencapsulated quercetin on a mouse model of Alzheimer’s disease
  68. Evaluation of the cytotoxicity, genotoxicity and mucus permeation capacity of several surface modified poly(anhydride) nanoparticles designed for oral drug delivery
  69. Zein nanoparticles for oral delivery of quercetin: Pharmacokinetic studies and preventive anti-inflammatory effects in a mouse model of endotoxemia
  70. New pharmaceutical approaches for the treatment of food allergies
  71. Amikacin loaded PLGA nanoparticles against Pseudomonas aeruginosa
  72. Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells
  73. Synthesis of Electroneutralized Amphiphilic Copolymers with Peptide Dendrons for Intramuscular Gene Delivery
  74. Oral delivery of camptothecin using cyclodextrin/poly(anhydride) nanoparticles
  75. Zein nanoparticles for oral folic acid delivery
  76. Study of Thermal Degradation of PLGA, PLGA Nanospheres and PLGA/Maghemite Superparamagnetic Nanospheres
  77. Interactions of poly (anhydride) nanoparticles with macrophages in light of their vaccine adjuvant properties
  78. In vivo study of the mucus-permeating properties of PEG-coated nanoparticles following oral administration
  79. Assessment of β-lapachone loaded in lecithin-chitosan nanoparticles for the topical treatment of cutaneous leishmaniasis in L. major infected BALB/c mice
  80. Toxicity evaluation of nanocarriers for the oral delivery of macromolecular drugs
  81. Mimicking microbial strategies for the design of mucus-permeating nanoparticles for oral immunization
  82. Controlled Release, Intestinal Transport, and Oral Bioavailablity of Paclitaxel Can be Considerably Increased Using Suitably Tailored Pegylated Poly(Anhydride) Nanoparticles
  83. Abstract 4067: Pluronic micelle-encapsulated Disulfiram targets cancer stem-like cells and reverses pan-resistance in acquired resistant breast cancer cell lines
  84. Zein-Based Nanoparticles Improve the Oral Bioavailability of Resveratrol and Its Anti-inflammatory Effects in a Mouse Model of Endotoxic Shock
  85. Casein nanoparticles as carriers for the oral delivery of folic acid
  86. Co-Encapsulated CpG Oligodeoxynucleotides and Ovalbumin in PLGA Microparticles; An in vitro and in vivo Study
  87. Topical treatment of L. major infected BALB/c mice with a novel diselenide chitosan hydrogel formulation
  88. Nanoparticles as Adjuvants for Vaccination
  89. Development of a Bacterial Nanoparticle Vaccine
  90. Liposome encapsulated Disulfiram inhibits NFκB pathway and targets breast cancer stem cells in vitro and in vivo
  91. Nanoparticle based-immunotherapy against allergy
  92. Pharmacokinetics and antitumor efficacy of paclitaxel–cyclodextrin complexes loaded in mucus-penetrating nanoparticles for oral administration
  93. Immunogenicity of Peanut Proteins Containing Poly(Anhydride) Nanoparticles
  94. Influence of Cyclodextrin Derivatives on In Vitro Release of Cyclosporine A from Poly(anhydride) Nanoparticles
  95. Nanoparticles as multifunctional devices for the topical treatment of cutaneous leishmaniasis
  96. Vaccine Delivery Systems for Veterinary Immunization
  97. Thermosensitive hydrogels of poly(methyl vinyl ether-co-maleic anhydride) – Pluronic® F127 copolymers for controlled protein release
  98. Superparamagnetic maghemite loaded poly (?- caprolactone) nanocapsules : characterization and synthesis optimization
  99. PLGA nanoparticles loaded with KMP-11 stimulate innate immunity and induce the killing of Leishmania
  100. Antigen Delivery Systems as Oral Adjuvants
  101. Cytotoxicity and Cell Interaction Studies of Bioadhesive Poly(anhydride) Nanoparticles for Oral Antigen/Drug Delivery
  102. Nanoparticle-based vaccine for mucosal protection against Shigella flexneri in mice
  103. Optimization of maghemite-loaded PLGA nanospheres for biomedical applications
  104. Towards a non-living vaccine against Shigella flexneri: From the inactivation procedure to protection studies
  105. Nanoparticules mucopénétrantes : véhicules pour l’administration orale du paclitaxel
  106. Radiomarcaje y estudios de biodistribución de nanopartículas poliméricas como adyuvantes para la vacunación oftálmica frente a la brucelosis
  107. Poly(ethylene oxide)-block-poly(n-butyl acrylate)-block-poly(acrylic acid) triblock terpolymers with highly asymmetric hydrophilic blocks: synthesis and aqueous solution properties
  108. Recent progress towards development of aShigellavaccine
  109. Development of poly(anhydride) nanoparticles loaded with peanut proteins: The influence of preparation method on the immunogenic properties
  110. Stabilized micelles as delivery vehicles for paclitaxel
  111. Conjunctival vaccination against Brucella ovis in mice with mannosylated nanoparticles
  112. Innovative Lead Compounds and Formulation Strategies As Newer Kinetoplastid Therapies
  113. Oral administration of paclitaxel with pegylated poly(anhydride) nanoparticles: Permeability and pharmacokinetic study
  114. Low efficacy of NcGRA7, NcSAG4, NcBSR4 and NcSRS9 formulated in poly-ɛ-caprolactone against Neospora caninum infection in mice
  115. Toxicity Studies of Poly(Anhydride) Nanoparticles as Carriers for Oral Drug Delivery
  116. Nuevas formas farmacéuticas para el tratamiento de enfermedades alérgicas
  117. Chapter 2.3. Nanostructures for Oral Vaccine Delivery
  118. Acellular vaccines for ovine brucellosis: a safer alternative against a worldwide disease
  119. Nanoparticulate Adjuvants and Delivery Systems for Allergen Immunotherapy
  120. Molecular buckets: cyclodextrins for oral cancer therapy
  121. Gantrez AN Nanoparticles for Ocular Delivery of Memantine: In vitro Release Evaluation in Albino Rabbits
  122. Mucosal immunization with Shigella flexneri outer membrane vesicles induced protection in mice
  123. Poly(methyl vinyl ether-co-maleic anhydride) nanoparticles as innate immune system activators
  124. Nanomedicine: Novel approaches in human and veterinary therapeutics
  125. Cyclodextrin/poly(anhydride) nanoparticles as drug carriers for the oral delivery of atovaquone
  126. Bioadhesive properties of poly(anhydride) nanoparticles coated with different molecular weights chitosan
  127. Cyclodextrin-poly(anhydride) nanoparticles as new vehicles for oral drug delivery
  128. Nanoparticles for the Oral Administration of Cancer Therapies
  129. Molecular Imaging Techniques to Study the Biodistribution of Orally Administered 99mTc-Labelled Naive and Ligand-Tagged Nanoparticles
  130. Poly(Anhydride) Nanoparticles Act as Active Th1 Adjuvants through Toll-Like Receptor Exploitation
  131. Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles
  132. Toxicity studies of poly(anhydride) nanoparticles
  133. Influence of dextran on the bioadhesive properties of poly(anhydride) nanoparticles
  134. Evaluation of particulate acellular vaccines against Brucella ovis infection in rams
  135. Influence of the chitosan nature on the transfection efficacy of DNA-loaded nanoparticles after hydrodynamic administration in mice
  136. Different approaches for determination of the attachment degree of polyethylene glycols to poly(anhydride) nanoparticles
  137. Poly anhydride nanoparticles as adjuvants for mucosal vaccination
  138. Combined hydroxypropyl-β-cyclodextrin and poly(anhydride) nanoparticles improve the oral permeability of paclitaxel
  139. New adjuvants: from empiricism to science
  140. A novel nanoparticulate adjuvant for immunotherapy with Lolium perenne
  141. Immunoadjuvant capacity of flagellin and mannosamine-coated poly(anhydride) nanoparticles in oral vaccination
  142. Design and influence of γ-irradiation on the biopharmaceutical properties of nanoparticles containing an antigenic complex from Brucella ovis
  143. Bioadhesive properties and biodistribution of cyclodextrin–poly(anhydride) nanoparticles
  144. Protection from Staphylococcus aureus mastitis associated with poly-N-acetyl β-1,6 glucosamine specific antibody production using biofilm-embedded bacteria
  145. Co-Delivery of Ovalbumin and CpG Motifs into Microparticles Protected Sensitized Mice from Anaphylaxis
  146. Allergen immunotherapy with nanoparticles containing lipopolysaccharide from Brucella ovis
  147. Stability of Poly(ε-caprolactone) Microparticles Containing Brucella ovis Antigens as a Vaccine Delivery System Against Brucellosis
  148. New methodologies to characterize the effectiveness of the gene transfer mediated by DNA-chitosan nanoparticles
  149. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology
  150. Evaluation of Bioadhesive Capacity and Immunoadjuvant Properties of Vitamin B12-Gantrez Nanoparticles
  151. Mannose-targeted systems for the delivery of therapeutics
  152. Nanomedicina: nanopartículas con aplicaciones médicas
  153. Development of bioadhesive amino-pegylated poly(anhydride) nanoparticles designed for oral DNA delivery
  154. Bioadhesive capacity and immunoadjuvant properties of thiamine-coated nanoparticles
  155. Albumin Nanoparticles
  156. Plant Protein-based Nanoparticles
  157. An HPLC with evaporative light scattering detection method for the quantification of PEGs and Gantrez in PEGylated nanoparticles
  158. Lyophilization of adenoviral vectors for gene therapy
  159. Gantrez® AN nanoparticles as an adjuvant for oral immunotherapy with allergens
  160. Protective immunity of biodegradable nanoparticle-based vaccine against an experimental challenge with Salmonella Enteritidis in mice
  161. Evaluation of bioadhesive potential and intestinal transport of pegylated poly(anhydride) nanoparticles
  162. Nanoparticles as Adjuvant-Vectors for Vaccination
  163. Intradermal immunization with ovalbumin-loaded poly-?-caprolactone microparticles conferred protection in ovalbumin-sensitized allergic mice
  164. Gamma Interferon Loaded onto Albumin Nanoparticles: In Vitro and In Vivo Activities against Brucella abortus
  165. Encapsulation of antigenic extracts of Salmonella enterica serovar
  166. Chemical and Biological Factors in the Control of Brucella and Brucellosis
  167. Bioadhesive Mannosylated Nanoparticles for Oral Drug Delivery
  168. Development of a Novel Vaccine Delivery System Based on Gantrez Nanoparticles
  169. Experiments on a sub-unit vaccine encapsulated in microparticles and its efficacy against Brucella melitensis in mice
  170. Brucella outer membrane complex-loaded microparticles as a vaccine against Brucella ovis in rams
  171. Optimization of the entrapment of bacterial cell envelope extracts into microparticles for vaccine delivery
  172. Simultaneous quantification of different cyclodextrins and Gantrez by HPLC with evaporative light scattering detection
  173. Salmonella-like bioadhesive nanoparticles
  174. Gentamicin-loaded microspheres for treatment of experimental Brucella abortus infection in mice
  175. Pegylated nanoparticles based on poly(methyl vinyl ether-co-maleic anhydride): preparation and evaluation of their bioadhesive properties
  176. Bioadhesive properties of pegylated nanoparticles
  177. Albumin Nanoparticles for the Intravitreal Delivery of Anticytomegaloviral Drugs
  178. Potential of Albumin Nanoparticles as Carriers for Interferon Gamma
  179. Protective ability of subcellular extracts from Salmonella Enteritidis and from a rough isogenic mutant against salmonellosis in mice
  180. Bioadhesive Properties of Gantrez Nanoparticles
  181. Potential of Albumin Nanoparticles as Carriers for Interferon Gamma
  182. Humoral immune response in hens naturally infected withSalmonellaEnteritidis against outer membrane proteins and other surface structural antigens
  183. Gentamicin-loaded microspheres for reducing the intracellular Brucella abortus load in infected monocytes
  184. Nanoparticles with specific bioadhesive properties to circumvent the pre-systemic degradation of fluorinated pyrimidines
  185. New Therapeutic Approaches for the Treatment of Brucella Infections: Gentamicin Entrapment into Drug Delivery Systems
  186. Influence of the co-encapsulation of different excipients on the properties of polyester microparticle-based vaccine against brucellosis
  187. In vivo sustained release of adenoviral vectors from poly(d,l-lactic-co-glycolic) acid microparticles prepared by TROMS
  188. Albumin nanoparticles improved the stability, nuclear accumulation and anticytomegaloviral activity of a phosphodiester oligonucleotide
  189. Fluconazole encapsulation in PLGA microspheres by spray-drying
  190. Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice
  191. Bovine Serum Albumin Modified the Intracellular Distribution and Improved the Antiviral Activity of an Oligonucleotide
  192. Influence of the surface characteristics of PVM/MA nanoparticles on their bioadhesive properties
  193. Corrigendum to: “Gantrez® AN as a new polymer for the preparation of ligand–nanoparticle conjugates”
  194. Loading of plasmid DNA into PLGA microparticles using TROMS (Total Recirculation One-Machine System): evaluation of its integrity and controlled release properties
  195. Modulation of the cellular immune response after oral or subcutaneous immunization with microparticles containing Brucella ovis antigens
  196. Gantrez® AN as a new polymer for the preparation of ligand–nanoparticle conjugates
  197. Albumin nanoparticles as carriers for a phosphodiester oligonucleotide
  198. Development of microparticles prepared by spray-drying as a vaccine delivery system against brucellosis
  199. Quantification of the bioadhesive properties of protein-coated PVM/MA nanoparticles
  200. RP–LC determination of 5-fluorouridine in nanoparticulate formulations
  201. Ocular disposition and tolerance of ganciclovir-loaded albumin nanoparticles after intravitreal injection in rats
  202. In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres
  203. Polyester Microparticles as a Vaccine Delivery System for Brucellosis: Influence of the Polymer on Release, Phagocytosis and Toxicity
  204. Efficacy of Ganciclovir-loaded Nanoparticles in Human Cytomegalovirus (HCMV)-infected Cells
  205. Adaptive Immune Responses of Legumin Nanoparticles
  206. In Vitro Antileishmanial Activity of Amphotericin B Loaded in Poly(ε-Caprolactone) Nanospheres
  207. A Brucella ovis antigenic complex bearing poly-ε-caprolactone microparticles confer protection against experimental brucellosis in mice
  208. Ganciclovir-loaded albumin nanoparticles: characterization and in vitro release properties
  209. Rapid determination of intramacrophagic amphotericin B by direct injection HPLC
  210. Bioadhesive potential of gliadin nanoparticulate systems
  211. In Vitro Reversion of Amphotericin B Resistance in Leishmania donovani by Poloxamer 188
  212. RESEARCH NOTE - Evaluation and Characterisation of Gliadin Nanoparticles and Isolates by Reversed-Phase HPLC
  213. Gentamicin encapsulation in PLA/PLGA microspheres in view of treating Brucella infections
  214. Determination of oligonucleotide ISIS 2922 in nanoparticulate delivery systems by capillary zone electrophoresis
  215. Development of a sensitive method for the determination of ganciclovir by reversed-phase high-performance liquid chromatography
  216. Biopolymer and polymer nanoparticles and their biomedical applications
  217. Distribution of Albumin Nanoparticles in Animals Induced with the Experimental Allergic Encephalomyelitis
  218. Preparation of Ulex europaeus lectin-gliadin nanoparticle conjugates and their interaction with gastrointestinal mucus
  219. Electrophoretic separation and characterisation of gliadin fractions from isolates and nanoparticulate drug delivery systems
  220. Gliadin nanoparticles: formation, all‐ trans‐retinoic acid entrapment and release, size optimization
  221. Gliadin nanoparticles: formation, all-trans-retinoic acid entrapment and release, size optimization
  222. Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract
  223. Interaction of amphotericin B with polymeric colloids
  224. Interaction of amphotericin B with polymeric colloids: 2. Effect of poloxamer on the adsorption of amphotericin B onto poly(ϵ-caprolactone) nanospheres
  225. Development of Drug-delivery Systems from Vegetal Proteins: All-trans-retinoic Acid-loaded Gliadin Nanoparticles
  226. Poly(ε-caprolacton) nanospheres as an alternative way to reduce amphotericin B toxicity
  227. Preparation of lectin-vicilin nanoparticle conjugates using the carbodiimide coupling technique
  228. Gliadin nanoparticles for the controlled release of all-trans-retinoic acid
  229. Development of Drug Delivery Systems from Vegetal Proteins: Legumin Nanoparticles
  230. Optimization and in vitro stability of legumin nanoparticles obtained by a coacervation method
  231. Mucin Interactions with Functionalized Polystyrene Latexes
  232. In vitro study of lectin-latex conjugates for specific bioadhesion
  233. Preparation and characterization of lectin-latex conjugates for specific bioadhesion
  234. Stability of some phenolic antioxidants in fatty preparations
  235. Determination of particle concentration in latexes by turbidimetry
  236. HPLC determination of antioxidant synergists and ascorbic acid in some fatty pharmaceuticals, cosmetics and food
  237. NANOPARTICLES FOR ORAL VACCINATION
  238. Study of the interactions between nanoparticles and intestinal mucosa